Merck & Co. Inc. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Behind the Scenes of Merck & Co's Latest Options Trends
Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...
Zacks.com on MSN1 天
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...
来自MSN1 天
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...
FierceBiotech4 天
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Merck’s Top-Seller Cements Status in Hard-to-Treat Breast Cancer
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...
Merck & Co. Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
bovnews3 天
Merck & Co Inc (MRK) Stock: Beyond the Surface of Its Performance?
Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In ...
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
Merck HPV疫苗试验结果积极
新泽西州拉威 - 全球医疗保健公司Merck & Co., Inc. (NYSE:MRK)今日宣布,其GARDASIL®9 HPV疫苗的三期临床试验在16至26岁日本男性中达到主要和次要终点。与安慰剂相比,该疫苗在减少九种HPV类型引起的持续性肛门生殖器感染方面显示出疗效。 这项名为V503-064的试验共招募了1,059名参与者,旨在减少HPV 6、11、16、18、31、33、45、52和58 ...
Evaxion 黑色素瘤试验中报告高响应率
哥本哈根 - 临床阶段生物科技公司 Evaxion Biotech A/S (NASDAQ: EVAX) 报告了其主要化合物 EVX-01 与 Merck & Co., Inc. 的抗 PD-1 疗法 KEYTRUDA® (pembrolizumab) 联合使用的二期试验中期结果令人鼓舞。这项针对晚期黑色素瘤患者的研究显示,16 名参与者中有 11 名达到了客观临床反应,总体响应率 (ORR) 为 ...